Recardio at ChinaBIO 2026
- 5 days ago
- 1 min read
San Francisco, April 1, 2026 - Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular and other diseases, announced today that it is participating in the ChinaBIO in Shanghai.
The ChinaBio Partnering Forum represents a significant gathering for global leaders, offering a platform for networking, collaboration, and strategic partnerships, with a focus on healthcare solutions and life sciences.
The conference is taking place on April 28-29, 2026 in Shanghai, with a digital partnering component from May 6-7, 2026.
Recardio is participating and presenting its latest advancements from its drug-based regenerative therapy and is giving a future outlook on new therapies and expansion programs.
About Recardio
Recardio Inc. is a late clinical-stage life science company focused on developing therapies for cardiovascular and other diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines critical for cardiac regeneration, resulting in healing cardiac tissue after an injury.
Recardio has received FDA and EMA clearance for a global pivotal phase III HEAL-MI clinical trial in acute myocardial infarction. This trial is planned to initiate in 2026 and will serve as the basis to apply for market authorization in major global markets. Recardio plans to fully develop its therapeutic platform for patients with various cardiovascular diseases. The company is headquartered in San Francisco, California, with operations in both the US and Europe.
For more information, visit: www.recardio.eu or contact pr@recardio.eu
